ORIGINAL PAPERS

   GASTROINTESTINAL CANCER

Clinical Outcomes Associated with Bevacizumab-Containing Treatment of Metastatic Colorectal Cancer: The BRiTE Observational Cohort Study

Mark Kozloff, Marianne Ulcickas Yood, Jordan Berlin, Patrick J. Flynn, Fairooz F. Kabbinavar, David M. Purdie, Mark A. Ashby, Wei Dong, Mary M. Sugrue, Axel Grothey, for the investigators of the BRiTE study
The Oncologist 2009; 14: 862-870; doi:10.1634/theoncologist.2009-0071
[Abstract] [Full Text] [PDF]  

SUMMARY: This report presents results of the BRiTE observational cohort study designed to elucidate safety and effectiveness outcomes associated with bevacizumab combined with chemotherapy as used in clinical practice for first-line treatment of metastatic colorectal cancer.

Lymphadenectomy for Gastric Adenocarcinoma: Should West Meet East?

Sam S. Yoon, Han-Kwang Yang
The Oncologist 2009; 14: 871-882; doi:10.1634/theoncologist.2009-0070
[Abstract] [Full Text] [PDF]  

SUMMARY: Significant variability exists among countries in the extent of lymphadenectomy that is performed for gastric cancer. This article reviews these differences as well as summarizes the evidence on the extent of lymphadenectomy that should be performed for gastric adenocarcinoma.

Perspectives and Attitudes on the Use of Adjuvant Chemotherapy and Trastuzumab in Older Adults with HER-2⁺ Breast Cancer: A Survey of Oncologists

Arti Hurria, F. Lennie Wong, Sumanta Pal, Cathie T. Chung, Smita Bhatia, Joanne Mortimer, George Somlo, Sara Hurvitz, Doojduen Villaluna, Arash Naeim
The Oncologist 2009; 14: 883-890; doi:10.1634/theoncologist.2009-0056
[Abstract] [Full Text] [PDF]  

SUMMARY: This study examines how patient age and health status impact oncologists' decisions to recommend adjuvant therapy in older women with human epidermal growth factor receptor–positive breast cancer. The findings suggest that, with increasing age and declining health status, oncologists are less likely to recommend chemotherapy plus trastuzumab and more likely to recommend single-agent trastuzumab or no therapy.

The Chronology of Distress, Anxiety, and Depression in Older Prostate Cancer Patients

Christian J. Nelson, Mark I. Weinberger, Eliana Balk, Jimmie Holland, William Breitbart, Andrew J. Roth
The Oncologist 2009; 14: 891-899; doi:10.1634/theoncologist.2009-0059
[Abstract] [Full Text] [PDF]  

SUMMARY: This study examines the relationship between age and psychological variables such as distress, anxiety, and depression within a sample of older prostate cancer patients, and finds that overall distress and anxiety decrease with age, whereas depressive symptoms increase with age.

Prognostic Significance of Epidermal Growth Factor Receptor Phosphorylation and Mutation in Head and Neck Squamous Cell Carcinoma

Takanori Hama, Yuki Yuza, Yoshimichi Saito, Jin O-uchi, Shu Kondo, Masataka Okabe, Hisashi Yamada, Takakuni Kato, Hiroshi Moriyama, Satoshi Kurihara, Mitsuyoshi Urashima
The Oncologist 2009; 14: 900-908; doi:10.1634/theoncologist.2009-0058
[Abstract] [Full Text] [PDF]  

SUMMARY: This study examines the frequencies of epidermal growth factor receptor (EGFR) genetic mutations as well as the expression/phosphorylation status of the EGFR protein in head and neck squamous cell carcinoma patients and attempts to elucidate associations between EGFR status and patient characteristics and disease-free survival. The study found that phosphorylated EGFR without mutations may be a marker of poor prognosis in these patients.

Vaccines for the Treatment of Non-Small Cell Lung Cancer: A Renewed Anticancer Strategy

Cesare Gridelli, Antonio Rossi, Paolo Maione, Marianna Luciana Ferrara, Vincenzo Castaldo, Paola Claudia Sacco
The Oncologist 2009; 14: 909-920; doi:10.1634/theoncologist.2009-0017
[Abstract] [Full Text] [PDF]  

SUMMARY: This paper reviews the main clinical trials involving several different cancer vaccines employed in the treatment of early and advanced stage NSCLC, focusing on those in advanced stages of development.

Controversies in the Treatment of Lymphoma with Autologous Transplantation

Alison J. Moskowitz, Craig H. Moskowitz
The Oncologist 2009; 14: 921-929; doi:10.1634/theoncologist.2009-0162
[Abstract] [Full Text] [PDF]  

SUMMARY: This review focuses on the controversial issues regarding high-dose therapy and autologous stem cell transplant for follicular lymphoma, mantle cell lymphoma, and peripheral T cell lymphoma.

Approval Summary: Pemetrexed in the Initial Treatment of Advanced/Metastatic Non-Small Cell Lung Cancer

Martin H. Cohen, Robert Justice, Richard Pazdur
The Oncologist 2009; 14: 930-935; doi:10.1634/theoncologist.2009-0092
[Abstract] [Full Text] [PDF]  

SUMMARY: Reported are the results of a postmarketing study to confirm and describe the clinical benefit of pemetrexed in patients with advanced or metastatic non-small cell lung cancer who have failed prior chemotherapy.

Patient-Related Barriers to Fatigue Communication in Cancer Patients Receiving Active Treatment

Shiow-Ching Shun, Yeur-Hur Lai, Fei-Hsiu Hsiao
The Oncologist 2009; 14: 936-943; doi:10.1634/theoncologist.2009-0048
[Abstract] [Full Text] [PDF]  

SUMMARY: This study explores barriers to reporting fatigue in cancer patients receiving active treatment and the factors significantly associated with those barriers. Assessing fatigue interference with daily life and identifying factors associated with barriers to reporting fatigue (i.e., type of cancer, religion, and the setting for receiving treatment) are suggested in order to provide better fatigue management in clinical settings.

Pharmacokinetics of Gemcitabine and Metabolites in a Patient with Double-Sided Nephrectomy: A Case Report and Review of the Literature

Stijn L.W. Koolen, Alwin D.R. Huitema, Robert S. Jansen, Theo van Voorthuizen, Jos H. Beijnen, Willem M. Smit, Jan H.M. Schellens
The Oncologist 2009; 14: 944-948; doi:10.1634/theoncologist.2009-0111
[Abstract] [Full Text] [PDF]  

SUMMARY: Presented is a case of poor tolerability of gemcitabine in a patient with complete renal failure resulting from nephrectomy of both kidneys.

Trabectedin

Meredith K. Chuk, Frank M. Balis, Elizabeth Fox
The Oncologist 2009; 14: 949; doi:10.1634/theoncologist.2009-0104erratum
[Full Text] [PDF]  

Sorafenib and Sunitinib

AeRang Kim, Frank M. Balis, Brigitte C. Widemann
The Oncologist 2009; 14: 949; doi:10.1634/theoncologist.2009-0088erratum
[Full Text] [PDF]  

To review many abstracts, check the boxes to the left of the titles you want, and click the 'Get All Checked Abstract(s)' button.